• Intravesical p21 mRNA-LNP Therapy in Bladder Cancer

  2026-09-10

  The 2026 FASEB Journal study developed chemically modified p21 mRNA-loaded lipid nanoparticles for localized intravesical treatment of bladder cancer. Its evidence links restoration of nuclear p21 to cell-cycle inhibition, DNA-damage accumulation, apoptosis, and tumor suppression with limited systemic distribution in an orthotopic mouse model.

• Ceftolozane-Tazobactam Resistance via AmpC/AmpD

  2026-09-09

  Deroche and colleagues combined engineered Pseudomonas aeruginosa mutants, sequential time-kill experiments, and semi-mechanistic PKPD modeling to separate the initial and adaptive effects of AmpC and AmpD mutations on ceftolozane-tazobactam activity. The study shows that combined mutations can produce substantially greater resistance than either mutation alone and demonstrates a framework for interpreting complex resistance phenotypes in clinical isolates.

• 2-APB for Intracellular Calcium Signaling

  2026-09-09

  2-APB is a practical perturbation tool for separating IP3R-dependent calcium release, store-operated calcium entry, and TRPC-linked signals in live-cell assays. This workflow connects calcium imaging with oxidative injury and cardiovascular signaling research while emphasizing solvent controls, concentration windows, and the compound’s important selectivity limits.

• 2X HyperFusion High-Fidelity Master Mix: Assay Design

  2026-09-08

  Discover how the 2X HyperFusion High-Fidelity Master Mix can support accurate DNA amplification across translational cancer workflows. This article connects the reagent’s proofreading chemistry with assay decisions inspired by a bufalin–CRISPR/Cas9 nanomedicine study while clearly separating PCR evidence from therapeutic evidence.

• Pcbp1, Mitochondria, and B Cell Antibody Responses

  2026-09-08

  Zhu and colleagues identify Pcbp1 as a posttranscriptional regulator that preserves mitochondrial complex I function, limits mitochondrial reactive oxygen species, and sustains protein translation in B cells. The study connects Pcbp1–Fdxr regulation with steady-state IgM production, germinal center development, and high-affinity antibody responses, while suggesting practical ways to measure translation in related models.

• Doxycycline in 3D Mechanobiology Research

  2026-09-07

  Doxycycline is more than a tetracycline antibiotic in modern biotechnology: its antimicrobial, antiproliferative, and metalloproteinase-inhibitory properties can materially influence 3D cell-matrix assays. This article explains how to use it as a controlled research variable alongside new findings on cell tumbling and nuclear mechanotransduction.

• Dual Methylation Drives MZF1 Splicing in EGFR-TKI Resistance

  2026-09-07

  This 2026 study identifies coordinated DNA 5-methylcytosine and RNA m5C regulation as a mechanism that shifts MZF1 splicing toward the zinc-binding-deficient MZF1S isoform during EGFR-TKI resistance. Its findings connect the UHRF1/DNMT1–NSUN7/YBX1 axis with altered SRSF1/SRSF3 binding, providing a mechanistic basis for resistance biomarkers and potential resensitization strategies in non-small-cell lung cancer.

• Dabigatran Etexilate: From Target to Assay

  2026-09-05

  Dabigatran etexilate is a direct thrombin inhibitor whose prodrug biology changes how anticoagulant assays should be designed and interpreted. This guide connects thrombin inhibition mechanism, plasma endpoints, solvent handling, and translational research decisions.

• Ziprasidone HCl: Receptor Signals to Tumor Redox

  2026-09-04

  Ziprasidone HCl is a pharmacologically complex tool for connecting dopaminergic and serotonergic signaling with GOT1-dependent tumor metabolism. This guide focuses on causal assay design, evidence maturity, and how to interpret receptor and redox readouts without conflating them.

• CIAV Replication Depends on Host CK2α–VP2 Binding

  2026-09-04

  The reference study identifies host CK2α as an essential cellular factor for chicken infectious anemia virus replication. By combining CK2α loss-of-function experiments with VP2 mutagenesis and reverse genetics, the authors show that the VP2 Ser182/Asp183 interface stabilizes VP2 and contributes to viral pathogenicity in chickens.

• Beyond MYC: Building a Translational Evidence Chain

  2026-09-03

  10058-F4 offers a target-proximal way to interrogate c-Myc/Max biology, apoptosis, leukemia models, and prostate cancer xenografts. This thought-leadership guide connects that pharmacology with emerging evidence that APEX2 supports TERT expression, while emphasizing model selection, orthogonal validation, formulation discipline, and the limits of preclinical interpretation.

• FK866 (APO866): A Translational NAD Strategy

  2026-09-03

  FK866 (APO866) turns NAD metabolism into a measurable therapeutic vulnerability, with particular relevance to hematologic cancer research and biomarker-led combination design. This article connects NAMPT inhibition, acute myeloid leukemia research, and recent evidence that RAS/PI3K pathway alterations can sensitize ovarian cancer models to PARP/NAMPT co-targeting.

• Pepstatin A: Practical Aspartic Protease Workflows

  2026-09-02

  Pepstatin A provides a focused way to interrogate pepsin, renin, HIV protease, and cathepsin D activity across enzyme, antiviral, and bone-cell models. This guide combines dose-design logic, cell-based workflow controls, and a cost-saving nascent-RNA sequencing insight for more interpretable experiments.

• MnTBAP Chloride: Redox Research Workflows

  2026-09-02

  MnTBAP Chloride gives researchers a mechanistic way to test whether mitochondrial superoxide contributes to oxidative injury, inflammation, or stress-related phenotypes. This workflow-focused guide connects cell protection assays with brain mitochondrial and behavioral studies while emphasizing controls, formulation, and interpretation limits.

• 3-Deazaadenosine Hydrochloride: Assay Logic

  2026-09-01

  3-Deazaadenosine hydrochloride is a selective S-adenosylhomocysteine hydrolase inhibitor for probing methylation-dependent biology. This guide focuses on causal assay design, interpretation of m6A-related findings, and controls that distinguish pathway-wide effects from the IGF2BP1-TUBB4B-FAK mechanism.

581 records 7/39 page Previous Next First page 上5页 678910 下5页 Last page